Analysts See $-0.01 EPS for Arch Therapeutics Inc (ARTH)

July 18, 2017 - By Vivian Currie

 Analysts See $ 0.01 EPS for Arch Therapeutics Inc (ARTH)

Investors wait Arch Therapeutics Inc (OTCMKTS:ARTH) to report on July, 27. its quarterly earnings Wall Street analysts expect $-0.01 earnings per share, $0.00 or 0.00 % from last year’s $-0.01 same quarter earnings. Arch Therapeutics Inc’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.01 EPS reproted in the previous quarter, The stock decreased 2.96% or $0.02 on July 17, reaching $0.66. About 796,025 shares traded or 57.34% up from the average. Arch Therapeutics Inc (OTCMKTS:ARTH) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Arch Therapeutics, Inc. is a development-stage company. The company has market cap of $99.49 million. The Firm operates as a biotechnology company. It currently has negative earnings. The Firm focuses on developing products to stop bleeding and control leaking (sealant) during surgery and trauma care.

More notable recent Arch Therapeutics Inc (OTCMKTS:ARTH) news were published by: Seekingalpha.com which released: “Arch Therapeutics Seals The Deal On Strong Trial Data For Its AC5 Hemostatic …” on August 16, 2016, also Marketwatch.com with their article: “Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering” published on February 21, 2017, Seekingalpha.com published: “Can Arch Therapeutics Stop The Bleeding… In Patients, That Is” on June 27, 2016. More interesting news about Arch Therapeutics Inc (OTCMKTS:ARTH) were released by: Seekingalpha.com and their article: “Tiny Arch Therapeutics Just Doubled: Time To Dump?” published on April 11, 2016 as well as Seekingalpha.com‘s news article titled: “The Cheapest Medical Device Stock I’ve Ever Seen” with publication date: June 26, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: